Jubilant Pharmova Share Price Today (JUBLPHARMA)
TODAY IN ONE LINE
JUBLPHARMA dropped 3.2% on light volume, lagging Nifty's -0.9% move, supported by recent strong earnings.
With a market cap of ₹15,641.41 Cr., it trades at a P/E of 39.79. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Jubilant Pharmova flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 15.2%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 22.4% YoY
- ●Poor Capital ReturnsLow ROE of 6.5%
- ●Promoter Pledging DetectedPledge activity recorded on 14-Aug-2025 19:03
Latest Jubilant Pharmova News
What changed recently?
Recent events, corporate actions, and announcements.
Jubilant Pharmova Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Jubilant Pharmova Limited, framed against the sector median so the premium or discount is obvious at a glance.
Jubilant Pharmova Limited trades at a P/E of 39.79× and P/B of 2.24×, against the Healthcare sector median P/E of 45.33×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Jubilant Pharmova Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Jubilant Pharmova Limited — derived from the live tape, not yesterday's close.
Jubilant Pharmova Limited last traded at ₹975.15 with an intraday range of ₹975–₹1,006.85 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹975.15| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1060.03 | +84.88 | +8.70% |
| R3 | 1028.18 | +53.03 | +5.44% |
| R2 | 1017.52 | +42.37 | +4.34% |
| R1 | 996.33 | +21.18 | +2.17% |
| PIVOT | 985.67 | 10.52 | 1.08% |
| CURRENT | 975.15 | — | — |
| S1 | 964.48 | -10.67 | -1.09% |
| S2 | 953.82 | -21.33 | -2.19% |
| S3 | 932.63 | -42.52 | -4.36% |
| S4 | 900.78 | -74.37 | -7.63% |
JUBLPHARMA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹985.5–₹1006.85
Trading Below opening range, showing Bearishness
Jubilant Pharmova Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Jubilant Pharmova Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Jubilant Pharmova Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹15,641.41 Cr. and reported EPS of ₹25.05.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 7,235 | 8,280 ▲ 14.4% |
| Sales Growth YoY %Derived | 979.31% | 14.45% |
| Other Income | 57 | 66 ▲ 16.2% |
| Total Income | 7,291 | 8,346 ▲ 14.5% |
| 2,317 | 2,644 ▲ 14.1% | |
| Gross ProfitDerived | 4,918 | 5,635 ▲ 14.6% |
| Gross Margin %Derived | 67.97% | 68.06% |
| 3,744 | 4,376 ▲ 16.9% | |
| EBITDA (Operating Profit)Derived | 1,174 | 1,260 ▲ 7.3% |
| OPM %Derived | 16.22% | 15.22% |
| 968 | 593 ▼ 38.8% | |
| Profit Before Tax (PBT) | 981 | 614 ▼ 37.4% |
| 144 | 217 ▲ 50.1% | |
| Effective Tax %Derived | 14.71% | 35.25% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 836 | 398 ▼ 52.5% |
| Less: Non-controlling Interests | -3 | -1 ▲ 67.7% |
| Net Profit (Owner's PAT)Derived | 839 | 399 ▼ 52.5% |
| Net Profit Margin %Derived | 11.60% | 4.81% |
| PAT Growth YoY %Derived | 10,787.16% | -52.53% |
| Earnings Per Share (EPS ₹) | 52.70 | 25.02 ▼ 52.5% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% |
| Share of Profit from Associates/JVs | -1 | -0 ▲ 40.0% |
| Other Comprehensive Income (Net of Tax) | 85 | 546 ▲ 542.1% |
| Total Expenses (incl. D&A & Interest) | 6,310 | 7,731 ▲ 22.5% |
| Material Cost % of RevenueDerived | 27.44% | 28.02% |
| Employee Cost % of RevenueDerived | 31.35% | 32.62% |
| Other Cost % of RevenueDerived | 20.40% | 20.23% |
| Interest Coverage (x)Derived | 3.35x | 3.87x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 7,465 | 9,111 ▲ 22.1% | 9,154 ▲ 0.5% | 6,099 ▼ 33.4% | 6,059 ▼ 0.6% | 6,282 ▲ 3.7% | 670 ▼ 89.3% | 7,235 ▲ 979.3% | 8,280 ▲ 14.4% | |
| Sales Growth YoY %Derived | — | 22.05% | 0.48% | -33.38% | -0.65% | 3.67% | -89.33% | 979.31% | 14.45% | |
| Other Income | 133 | 36 ▼ 73.1% | 47 ▲ 32.7% | 18 ▼ 62.8% | 82 ▲ 366.4% | 38 ▼ 53.4% | 7 ▼ 82.1% | 57 ▲ 726.8% | 66 ▲ 16.2% | |
| Total Income | 7,598 | 9,147 ▲ 20.4% | 9,202 ▲ 0.6% | 6,116 ▼ 33.5% | 6,141 ▲ 0.4% | 6,320 ▲ 2.9% | 677 ▼ 89.3% | 7,291 ▲ 976.7% | 8,346 ▲ 14.5% | |
2,869 | 3,522 ▲ 22.8% | 3,141 ▼ 10.8% | 1,536 ▼ 51.1% | 1,488 ▼ 3.1% | 1,878 ▲ 26.2% | 214 ▼ 88.6% | 2,317 ▲ 982.4% | 2,644 ▲ 14.1% | ||
| Gross ProfitDerived | 4,596 | 5,589 ▲ 21.6% | 6,014 ▲ 7.6% | 4,563 ▼ 24.1% | 4,571 ▲ 0.2% | 4,404 ▼ 3.7% | 456 ▼ 89.6% | 4,918 ▲ 977.9% | 5,635 ▲ 14.6% | |
| Gross Margin %Derived | 61.57% | 61.34% | 65.69% | 74.81% | 75.44% | 70.10% | 68.06% | 67.97% | 68.06% | |
3,171 | 3,850 ▲ 21.4% | 4,067 ▲ 5.6% | 3,166 ▼ 22.1% | 3,486 ▲ 10.1% | 3,628 ▲ 4.1% | 366 ▼ 89.9% | 3,744 ▲ 922.5% | 4,376 ▲ 16.9% | ||
| EBITDA (Operating Profit)Derived | 1,425 | 1,739 ▲ 22.0% | 1,947 ▲ 12.0% | 1,396 ▼ 28.3% | 1,085 ▼ 22.3% | 776 ▼ 28.5% | 90 ▼ 88.4% | 1,174 ▲ 1203.0% | 1,260 ▲ 7.3% | |
| OPM %Derived | 19.09% | 19.09% | 21.27% | 22.90% | 17.91% | 12.36% | 13.44% | 16.22% | 15.22% | |
699 | 310 ▼ 55.6% | 715 ▲ 130.2% | 512 ▼ 28.4% | 527 ▲ 3.0% | 685 ▲ 30.0% | 49 ▼ 92.9% | 968 ▲ 1895.5% | 593 ▼ 38.8% | ||
| Profit Before Tax (PBT) | 859 | 904 ▲ 5.2% | 1,211 ▲ 33.9% | 860 ▼ 29.0% | 640 ▼ 25.5% | 16 ▼ 97.6% | 15 ▼ 5.7% | 981 ▲ 6601.5% | 614 ▼ 37.4% | |
225 | 327 ▲ 45.5% | 312 ▼ 4.4% | 297 ▼ 4.8% | 217 ▼ 26.8% | 93 ▼ 57.4% | 10 ▼ 89.4% | 144 ▲ 1375.5% | 217 ▲ 50.1% | ||
| Effective Tax %Derived | 26.15% | 36.16% | 25.80% | 34.57% | 33.95% | 596.65% | 66.80% | 14.71% | 35.25% | |
| Profit/Loss from Discontinued Ops | — | — | — | 262 | — ▼ 100.0% | — | — | — | — | |
| Total Profit for Period | 634 | 577 ▼ 9.0% | 898 ▲ 55.7% | 836 ▼ 7.0% | 413 ▼ 50.6% | -65 ▼ 115.7% | 7 ▲ 111.2% | 836 ▲ 11403.4% | 398 ▼ 52.5% | |
| Less: Non-controlling Interests | — | 3 | — ▼ 100.0% | -0 | -1 ▼ 253.8% | -4 ▼ 323.9% | -0 ▲ 88.7% | -3 ▼ 604.5% | -1 ▲ 67.7% | |
| Net Profit (Owner's PAT)Derived | 634 | 574 ▼ 9.5% | 898 ▲ 56.4% | 836 ▼ 6.9% | 414 ▼ 50.5% | -61 ▼ 114.7% | 8 ▲ 112.6% | 839 ▲ 10787.2% | 399 ▼ 52.5% | |
| Net Profit Margin %Derived | 8.50% | 6.31% | 9.81% | 13.71% | 6.83% | -0.97% | 1.15% | 11.60% | 4.81% | |
| PAT Growth YoY %Derived | — | -9.45% | 56.36% | -6.94% | -50.48% | -114.73% | 112.64% | 10,787.16% | -52.53% | |
| Earnings Per Share (EPS ₹) | 39.83 | 36.07 ▼ 9.4% | 56.39 ▲ 56.3% | 52.48 ▼ 6.9% | 25.99 ▼ 50.5% | -3.83 ▼ 114.7% | 0.48 ▲ 112.5% | 52.70 ▲ 10879.2% | 25.02 ▼ 52.5% | |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | 11 | -10 ▼ 188.7% | 12 ▲ 222.7% | 2 ▼ 80.3% | -1 ▼ 120.7% | -0 ▲ 40.0% | |
| Other Comprehensive Income (Net of Tax) | 65 | -14 ▼ 121.1% | 33 ▲ 340.3% | 174 ▲ 426.3% | 244 ▲ 40.0% | 220 ▼ 9.6% | 5 ▼ 97.5% | 85 ▲ 1462.5% | 546 ▲ 542.1% | |
| Total Expenses (incl. D&A & Interest) | 6,739 | 8,243 ▲ 22.3% | 7,991 ▼ 3.1% | 5,256 ▼ 34.2% | 5,501 ▲ 4.7% | 6,305 ▲ 14.6% | 663 ▼ 89.5% | 6,310 ▲ 852.5% | 7,731 ▲ 22.5% | |
| Material Cost % of RevenueDerived | 35.88% | 36.03% | 34.08% | 22.12% | 22.26% | 26.53% | 27.17% | 27.44% | 28.02% | |
| Employee Cost % of RevenueDerived | 20.84% | 21.14% | 23.24% | 31.53% | 33.72% | 34.48% | 33.06% | 31.35% | 32.62% | |
| Other Cost % of RevenueDerived | 21.63% | 21.12% | 21.18% | 20.38% | 23.81% | 23.27% | 21.56% | 20.40% | 20.23% | |
| Interest Coverage (x)Derived | 3.55x | 6.22x | 5.17x | 5.69x | 4.84x | 1.18x | 1.91x | 3.35x | 3.87x |
Jubilant Pharmova segment analysis : revenue and profit mix.
Disclosed business segments at Jubilant Pharmova with their share of revenue and profit, switchable between consolidated and standalone reporting.
Jubilant Pharmova discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Jubilant Pharmova Limited.
Our AI distills the core fundamental drivers supporting Jubilant Pharmova Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Jubilant Pharmova Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding of 47.68% ensures stable management commitment and alignment.
Operating margin of 9.96% demonstrates reasonable cost control efficiency in operations.
TTM revenue growth of 18.7% indicates solid top-line momentum despite earnings pressure.
Positive operating cash flow of ₹369 Cr supports operational liquidity and debt servicing.
Diversified portfolio across radiopharma, generics, CDMO reduces concentration risk significantly.
Key Risks.
Latest quarterly EPS declined 22.3% YoY despite revenue growth, signaling earnings contraction.
TTM EPS declined 22.4% YoY, reflecting significant profitability deterioration year-over-year.
P/E of 39.09x suggests overvaluation relative to earnings quality and peer benchmarks.
ROE of 6.55% and ROCE of 8.99% lag industry benchmarks substantially, weak capital efficiency.
Net profit margin of 5.28% TTM trails peer averages significantly, indicating margin pressure.
Flip Conditions.
Valuation risk. a P/E above 52 (~1.1× the sector multiple of 45.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.01. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Jubilant Pharmova Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Jubilant Pharmova Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Jubilant Pharmova Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Jubilant Pharmova Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Jubilant Pharmova Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Jubilant Pharmova Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Jubilant Pharmova Limited stood at 51.5% of traded volume, against a 20-day average of 47.9%.
Jubilant Pharmova announcements: results, concalls, ratings, M&A.
Filings Jubilant Pharmova sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Jubilant Pharmova files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 134 documents below.
Shareholders meeting
Jubilant Pharmova Limited has informed the Exchange regarding Notice of Postal Ballot
General Updates
Jubilant Pharmova Limited has informed the Exchange about General Updates
General Updates
Jubilant Pharmova Limited has informed the Exchange about General Updates
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Jubilant Pharmova Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Copy of Newspaper Publication
Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Press Release
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Press Release
Jubilant Pharmova dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Jubilant Pharmova has declared, sequenced by announce and record date.
Jubilant Pharmova corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Jubilant Pharmova insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Jubilant Pharmova as reported to SEBI — buying and selling signals from the people who know the business best.
Jubilant Pharmova insider activity below tracks 6 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Jubilant Employees Welfare Trust | Insider | 09 Mar 2026 | buy | +11.3 K | ₹92.79 L | ₹820.85 |
| Jubilant Employees Welfare Trust | Insider | 09 Mar 2026 | buy | +11.3 K | ₹92.79 L | ₹820.85 |
| Jubilant Employees Welfare Trust | Insider | 09 Mar 2026 | buy | +11.3 K | ₹92.79 L | ₹820.85 |
| Jubilant Enpro Private Limited | Insider | 13 Jun 2025 | sell | −21.16 L | ₹224.3 Cr. | ₹1,060.00 |
| SPB Trustee Company Private Limited and SS Trustee Company Private Limited | Insider | 13 Jun 2025 | sell | −7.00 L | ₹74.2 Cr. | ₹1,060.00 |
| Nikita Resources Private Limited | Insider | 13 Jun 2025 | sell | −19.62 L | ₹208.09 Cr. | ₹1,060.37 |
About Jubilant Pharmova Limited: business, sector, key facts.
What Jubilant Pharmova Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Jubilant Pharmova Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: JUBLPHARMA, BSE: 530019.
Jubilant Pharmova Limited is a globally integrated pharmaceutical company with a presence in India, the Americas, Europe, and other international markets. The company's operations are structured across six distinct segments, each contributing to its diverse portfolio of products and services within the pharmaceutical industry.
The Radiopharma segment focuses on the development and supply of radiopharmaceuticals. These specialized products play a crucial role in the diagnosis and treatment of various conditions, including cancer, pulmonary embolism, and coronary artery disease. This segment caters to the needs of healthcare providers requiring advanced diagnostic and therapeutic tools.
The Allergy Immunotherapy segment specializes in providing diagnostic tools for allergy testing, along with the production and distribution of venom and allergy immunotherapy products. This segment addresses the growing need for effective allergy management and treatment, targeting allergists and healthcare facilities.
Jubilant Pharmova's Contract Development and Manufacturing Organisation (CDMO) – Sterile Injectables segment offers contract manufacturing services for a wide range of sterile injectable products. This includes liquids, ointments, creams, and ampoules. The company acts as a manufacturing partner for other pharmaceutical companies, providing expertise and capacity in sterile injectables production.
The Generics segment focuses on the development, manufacturing, distribution, and marketing of generic pharmaceutical formulations across various therapeutic areas. These areas include cardiovascular health, central nervous system disorders, gastrointestinal issues, antibiotics, and other multispecialty treatments. This segment competes in the broader market for affordable and accessible medications.
Another CDMO segment, focusing on Contract Research, Development, and Manufacturing Organisation, provides comprehensive drug discovery and development services, including the production of Active Pharmaceutical Ingredients (APIs). This segment plays a crucial role in supporting the pharmaceutical industry's research and development efforts.
Finally, the Proprietary Novel Drugs segment concentrates on developing and delivering patient-focused biopharmaceutical solutions addressing unmet medical needs primarily in oncology and autoimmune diseases. This segment reflects the company's commitment to innovation and the development of novel treatments for serious illnesses.
In summary, Jubilant Pharmova operates across the pharmaceutical value chain, from research and development to manufacturing and distribution, serving a diverse range of clients including pharmaceutical companies, biotech firms, group purchasing organizations, allergists, and hospitals. The company's diversified business model positions it for growth and adaptability within the dynamic global pharmaceutical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Jubilant Pharmova Limited (JUBLPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Jubilant Pharmova Limited (JUBLPHARMA)?
The current share price of Jubilant Pharmova Limited (JUBLPHARMA) is ₹975.15. Today, the stock has declined by ₹32.65 (3.24%), trading in a range of ₹975 to ₹1,006.85. The stock opened at ₹1,006.85 with a trading volume of 55,049 shares.
02Is Jubilant Pharmova Limited stock a good investment for long-term?
Jubilant Pharmova Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,641.41 crores, P/E ratio of 39.79, ROE of 6.55%, and ROCE of 8.99%. The dividend yield stands at 0.52%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Jubilant Pharmova Limited stock?
The 52-week high price of Jubilant Pharmova Limited (JUBLPHARMA) is ₹1,248, while the 52-week low is ₹786.05. Currently trading at ₹975.15, the stock is 40.9% away from its 52-week low and 21.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Jubilant Pharmova Limited stock at the current price?
Whether to buy Jubilant Pharmova Limited stock at ₹975.15 depends on multiple factors. The stock is currently trading with a P/E ratio of 39.79 and P/B ratio of 2.24. Today's performance shows a loss of 3.24%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Jubilant Pharmova Limited and when is the next dividend?
Jubilant Pharmova Limited offers a dividend yield of 0.52%, which means for every ₹100 invested at the current price of ₹975.15, you can expect to receive approximately ₹0.52 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Jubilant Pharmova Limited?
Jubilant Pharmova Limited's key financial metrics include: P/E Ratio: 39.79, P/B Ratio: 2.24, ROE: 6.55%, ROCE: 8.99%, Dividend Yield: 0.52%, EPS: ₹25.05, Book Value: ₹448.5, and Debt-to-Equity: 0.51. The company's market cap stands at ₹15,641.41 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Jubilant Pharmova Limited stock performing today in the market?
Jubilant Pharmova Limited stock opened at ₹1,006.85 and is currently trading at ₹975.15, showing a decline of ₹32.65 (3.24%). The intraday high is ₹1,006.85 and low is ₹975. The trading volume stands at 55,049 shares, indicating moderate market participation today.
08What is the P/E ratio of Jubilant Pharmova Limited and what does it indicate?
Jubilant Pharmova Limited has a Price-to-Earnings (P/E) ratio of 39.79, which means investors are willing to pay ₹39.79 for every ₹1 of earnings. With an EPS of ₹25.05, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Jubilant Pharmova Limited (JUBLPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.